The cost-effectiveness of neonatal screening for cystic fibrosis: An analysis of alternative scenarios using a decision model

Cost Effectiveness and Resource Allocation

Volumn 3, Issue , 2005, Pages

  Simpson, Neil ^a   Anderson, Rob ^b   Sassi, Franco ^c   Pitman, Alexandra ^c   Lewis, Peter ^d   Tu, Karen ^e,f   Lannin, Heather ^c  

^a Department of Child Health ^*  (United Kingdom)

^b UNIVERSITY OF EXETER   (United Kingdom)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^d UNIVERSITY OF BATH   (United Kingdom)

^e UNIVERSITY OF TORONTO   (Canada)

^f INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TRYPSIN;

ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DNA DETERMINATION; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; HYPOTHESIS; IMMUNOREACTIVITY; INCIDENCE; LIFESPAN; NEWBORN; NEWBORN SCREENING; ONSET AGE; OUTCOME ASSESSMENT; PRENATAL DIAGNOSIS; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; UNITED KINGDOM;

EID: 33646136004     PISSN: 14787547     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-3-8     Document Type: Article

References (44)

1. Dodge JA, Morison S, Lewis PA, Coles E, Geddes D, Russel G, et al.: Cystic Fibrosis in the United Kingdom, 1968-1988: incidence, population and survival. Pediatr & Perinat Epidemiol 1993, 2:157-166.
2. Dodge JA, Morison S, Lewis PA, Coles E, Geddes D, Russel G, et al.: Incidence, population and survival of cystic fibrosis in the UK, 1968-95. Arch Dis Child 1997, 77:493-496.
3. Murray J, Cuckle H, Taylor G, Littlewood J, Hewison J: Screening for cystic fibrosis. Health Technology Assessment 1999, 3(8):.
4. Farrell PM, Kosorok MR, Laxova A, Guanghong S, Koscik R, Bruns T, et al.: Nutritional benefits of neonatal screening for cystic fibrosis. N Engl J Med 1997, 337:963-969.
5. Chatfield S, Owen G, Ryley H, Williams J, Alfaham M, Goodchild M, et al.: Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening. Arch Dis Child 1991, 66:29-33.
6. Kuzemko JA: Neonatal screening for cystic fibrosis. Lancet 1986, i:327-328.
7. Dankert-Roelse J, Meeman GJ, Martijin A, Kate LP, Knol K: Survival and clinical outcome in patients with cystic fibrosis, with or without neonatal screening. J Pediatr 1989, 114:262-267.
8. Waters D, Wilken B, Irwig L, Van Asperen P, Mellis C, Simpson J, et al.: Clinical outcomes of newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 1999, 80:F1-F7.
9. Gregg RG, Wilfond BS, Farrell P, Laxova A, Hassemer D, Mischler E: Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. American Journal of Human Genetics 1993, 52:616-626.
10. Dauphinais RM: A cost-analysis of blood spot screening of newborns for cystic fibrosis. J Clin Immunoassay 1992, 15:121-125.
11. Farrell PM, Mischler EH: Newborn screening for cystic fibrosis. Advances in Pediatrics 1992, 39:35-70.
12. Pauly MV: The Economics of Cystic Fibrosis. Boston, John Wright, PSG 1983.
13. Sonnenberg F, Beck R: Markov Models in medical decision making: a practical guide. Medical Decision Making 1993, 13:322-338.
14. Littlewood JM, Cross E: Present day treatment of cystic fibrosis: its content and cost. Clinical Economics in Gastroenterology 1999:220-249.
15. Simpson N, Randall R, Lenton S, Walker S: Audit of neonatal screening programme for phenylketonuria and congenital hypothyroidism. Arch Dis Child 1997, 47:228-234.
16. Torgerson DJ, Raftery J: Economics notes - Discounting. BMJ 1999, 319:914-915.
17. Orenstein D, Nixon PA, Ross EA, Kaplan RM: The quality of well-being in cystic fibrosis. Chest 1989, 92:344-347.
18. Orenstein D, Pattishall EN, Nixon PA, Ross EA, Kaplan RM: Quality of well-being before and after antibiotic treatment of pulmonary exacerbation on patients with cystic fibrosis. Chest 1990, 98:1081-1084.
19. Bowling A: Measuring Health - a review of Quality of Life measurement scales. In Milton Keynes Open Clinical Press; 1991.
20. Congleton J, Hodson M, Duncan-Skingle F: Quality of life in adults with cystic fibrosis. Thorax 1996, 51:936-940.
21. Corey M, Farewell V: Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996, 143:1007-1017.
22. Simpson N: Audit of time for midwives to explain cystic fibrosis screening. Unpublished 1999.
23. Pollitt R, Green A, McCabe C, Booth A, Cooper N, Leonard J, et al.: Neonatal screening for inborn errors of metabolism: cost, yield and outcome (Review). Health Technology Assessment 1997, 1(7):.
24. Lai HJ, Cheng Y, Cho H, Kosorok MR, Farrel P: Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis. American J Epidemiol 2004, 159(6):537-546.
25. Koscik RL, Farrel PM, Kosorok MR, Zaremba KM, Laxova A, Lai HC, et al.: Cognitive function of children with cystic fibrosis: deleterious effect of early malnutrition. Pediatrics 2004, 113(6):1549-1558.
26. Assael BM, Castellani C, Ocampo MB, Iansa P, Callegaro A, Valsecchi MG: Epidemiology and survival analysis of cystic fibrosis In an area of intense neonatal screening over 30 years. American Journal of Epidemiology 2002, 156(5):397-401.
27. Siret D, Bretaudeau G, Branger B, Dabadie A, Dagorne M, David V, de Braekeleer M, et al.: Comparing the clinical evolution of cystic fibrosis screened neonatally to that of cystic fibrosis diagnosed from clinical symptoms: a 10-year retrospective study in a French region (Brittany). Pediatric Pulmonology 2003, 35(5):342-349.
28. Wang SS, FitzSimmons SC, O'Leary LA, Rock MJ, Gwinn ML, Khoury MJ: Early diagnosis of cystic fibrosis in the new-born period and risk of Pseudomonas aeruginosa acquisition in the first 10 years of life: a registry-based longitudinal study. Pediatrics 2001, 107(2):274-279.
29. Lewis P, Morison S, Dodge J, Geddes D, Coles E, Russell G, et al.: Survival estimates for adults with cystic fibrosis born in the United Kingdom between 1947 and 1967. Thorax 1999, 54:420-422.
30. Kotwicki RJ, Condra L, Vereulen L, Wolf T, Douglas J, Farrel PM: Assessing the quality of life in children with cystic fibrosis. Western Medical Journal 2001, 100(5):50-54.
31. Weinstein M, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al.: Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR Task Force on Good Research Practices - Modelling Studies. Value in Health 2003, 6(1):9-17.
32. Sassi F, McKee M, Roberts J: Economic evaluation of diagnostic technology: methodological challenges and viable solutions. Int J TechnoLol assessment in Health Care 1997, 13(4):613-630.
33. Shannon N, Evans S, Pollitt R, Quarrell O: Follow up of Delta F508 detected as a result of neonatal screening in the Trent Region. J Med Genet 1997, 34(suppl 1):P6.05.
34. Ranieri E, Lewis B, Morris C, Wilcken B: Neonatal screening using combined biochemical and DNA based techniques. Cystic Fibrosis - current topics 1996.
35. Wiebe K, Wahlers T, Harringer W, vd Hardt H, Fabel H, Haverich A: Lung transplantation for cystic fibrosis - a single centre experience over 8 years. European Journal of Cardio-Thoracic Surgery 1998, 14(2):191-196.
36. Coueitil J, Soubrane O, Houssin D, Dousset B, Chevalier P: Combined heart-lung-liver, double lung-liver, and isolated liver transplantation for cystic fibrosis in children. Transplant International 1997, 10(1):33-39.
37. Whitehead B, Helms P, Goodwin M, Martin I, Scott J, Smyth R, et al.: Heart-lung transplantation for cystic fibrosis. 2: Outcome. Archives of Disease in Childhood 1991, 66:1022-1026.
38. Balfour-Lynn I, Martin I, Whitehead B, Rees P, Elliot M, de Leval M: Heart-lung transplantation for patients under 10 with cystic fibrosis. Archives of Disease in Childhood 1997, 76:38-40.
39. Busschbach J, Horikx P, van den Bosch J, Brutal de la Riviere A, de Charro F: Measuring the quality of life before and after bilateral lung transplantation in patients with cystic fibrosis. Chest 1994, 105(3):911-917.
40. Robson M, Abbott J, Webb K, Dodd M, Walsworth-Bell J: A cost description of an adult cystic fibrosis unit and cost analysis of different categories of patients. Thorax 1992, 47:684-689.
41. Watson EK, Williamson R, Chapple J: Attitudes to carrier screening for cystic fibrosis: a survey of health care professionals, relatives of sufferers and other members of the public. Br J Gen Pract 1991, 41:237-240.
42. Watson EK, Marchant J, Bush A, Williamson B: Attitudes towards prenatal diagnosis and carrier screening for cystic fibrosis among the parents of patients in a paediatric cystic fibrosis clinic. J Med Genet 1992, 29:490-491.
43. Conway SP, Allenby K, Pond MN: Patient and parental attitudes toward genetic screening and its implications at an adult cystic fibrosis clinic. Clin Gen 1994, 45:308-312.
44. Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosefeld M, et al.: Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. In Morbidity & mortality weekly report Volume 53. Issue RR-13 Centre for Disease Control. Atlanta, Georgia, USA; 2004:1-36.